Kiniksa Pharmaceuticals International, plc (KNSA)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United Kingdom
Exchange: NASDAQ
Market cap: $6.03B
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Latest financial period: March 31, 2026
Filed with the SEC: April 28, 2026
Estimated earnings date: October 27, 2026
Profit #800 of 1484 companies
| | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|
| ROE/ROA | 46.2% | 34.3% | 34.0% | 23.3% |
Growth #24 of 1484 companies
Payout #1117 of 1484 companies
Safety #510 of 1484 companies
Price #1170 of 1484 companies
